Czech Neurotech Startup Stimvia Brings AI To Non-Invasive BCI

Stimvia: Revolutionizing Neurological Treatment with Non-Invasive Neuromodulation

Lukáš Doskočil, the founder and CEO of Stimvia, a Czech startup, has introduced a groundbreaking non-invasive neuromodulation system known as URIS. This innovative technology uses electrical pulses to stimulate deep brain structures through the leg, specifically targeting the peroneal nerve behind the knee. Initially designed to treat overactive bladder, URIS has shown promising results in managing a variety of neurological disorders such as Parkinson’s disease, multiple sclerosis, and Restless Leg Syndrome.

Doskočil describes URIS as a “hack” into the brain, bypassing the need for invasive implants or surgery. By utilizing proprietary non-invasive electrodes, the system sends electrical signals along nerve pathways to the prefrontal cortex. This approach has been validated through functional MRI studies, demonstrating stimulation effects in deep brain structures in a non-invasive manner, a feat never achieved before.

Clinical studies testing URIS for Parkinson’s disease have garnered attention in the medical community. Research conducted at Ostrava University Hospital revealed significant improvements in motor symptoms and quality of life among Parkinson’s patients using URIS. Additionally, the device has shown potential in treating bladder dysfunction, outperforming traditional nerve stimulation methods without the need for needles or surgery.

Stimvia’s URIS device is accompanied by a user-friendly app that collects data from each session, monitors symptoms, and adjusts the stimulation protocol accordingly. The latest version features an AI-powered virtual assistant that optimizes electrode placement and pulse parameters in real time, providing personalized treatment based on real-time feedback from the body.

Despite being a smaller player in the industry, Stimvia has made significant strides with its URIS technology. With manufacturing based in Pardubice, CZ, the company has raised $8 million and is gearing up for a Series A round. Stimvia has already shipped over 200 units and is expanding its presence across Europe, with plans for FDA approval in the United States.

Doskočil acknowledges the challenges of navigating Europe’s fragmented reimbursement landscape and sees the U.S. market as a game-changer for Stimvia. The company is establishing a commercial team in Miami and planning investigator-led trials to replicate its European success on a larger scale.

Stimvia’s innovative approach to non-invasive neuromodulation offers new hope for patients with various brain-related conditions. By addressing the root cause of these disorders through targeted stimulation, Stimvia is paving the way for a paradigm shift in neurological treatment, transforming lives without the need for invasive procedures.